Cipher Pharmaceuticals Inc. (TSE:CPH – Free Report) (NASDAQ:CPHR) – Research analysts at Stifel Canada boosted their Q4 2025 earnings estimates for shares of Cipher Pharmaceuticals in a report released on Thursday, October 16th. Stifel Canada analyst J. Keywood now anticipates that the company will post earnings of $0.28 per share for the quarter, up from their prior estimate of $0.27. The consensus estimate for Cipher Pharmaceuticals’ current full-year earnings is $1.29 per share.
Cipher Pharmaceuticals Stock Up 1.5%
TSE:CPH opened at C$14.92 on Monday. The firm’s 50-day moving average price is C$15.47 and its 200-day moving average price is C$13.66. The company has a market capitalization of C$378.88 million, a PE ratio of 32.43 and a beta of 0.77. The company has a debt-to-equity ratio of 41.22, a current ratio of 2.00 and a quick ratio of 2.67. Cipher Pharmaceuticals has a 1-year low of C$10.61 and a 1-year high of C$17.50.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company’s geographical segments include Canada and the United States.
Further Reading
- Five stocks we like better than Cipher Pharmaceuticals
- What Are the U.K. Market Holidays? How to Invest and Trade
- Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet
- How to Choose Top Rated Stocks
- 3 High-Yield Banks for Investors to Buy on the Dip
- What is a Dividend King?
- 5 Surprising Stocks Set to Benefit From a Future Robotics Boom
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
